Evidence map›Paper›PMID 33489808›Full record

ReviewTranslational lung cancer research2020

A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.

Yue Zhou, Fan Yu, Yang Zhao, Ya Zeng, Xi Yang, Li Chu, Xiao Chu, Yida Li, Liqing Zou, Tiantian Guo and 2 more

Registry-linked trialOpen access · diamondAbstract readReview
In one paragraph

Review in Translational lung cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07014202 (Comparing Consolidation Radiotherapy Versus No Radiotherapy for Oligoresidual Disease After First-line Chemotherapy Plus Immunotherapy in Advanced Non-Small Cell Lung Cancer), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07014202 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Comparing Consolidation Radiotherapy Versus No Radiotherapy for Oligoresidual Disease After First-line Chemotherapy Plus Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Prospective, Randomized Controlled Phase II Clinical Trial

TypeinterventionalSponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2025 to 2027Enrolled224ConditionsNon-Small Cell Lung CancerArmsImmunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy, Immunotherapy (with or without chemotherapy) maintenance therapy
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yue ZhouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fan YuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yang ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ya ZengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xi YangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Li ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiao ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yida LiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Liqing ZouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Tiantian GuoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhengfei ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jianjiao NiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy, along with other loco-regional interventions, is conventionally utilized as a palliative approach to alleviate symptoms and mitigate oncological emergencies in advanced non-small cell lung cancer (NSCLC). Thanks to the ongoing improvement of medical treatments in the last decade, such as targeted therapy and immunotherapy, the survival of patients with advanced NSCLC has been considerably prolonged, making it feasible and clinically beneficial for radiotherapy to play a more active role in highly selected subpopulations. In this review, we will focus on the evolving roles of radiotherapy in advanced NSCLC. First of all, among patients who are initially unable to tolerate aggressive treatment due to severe symptoms caused by metastases and/or tumor emergencies, timely radiotherapy could significantly improve their performance status (PS) and general condition, thus giving them a chance for intensive treatment and prolonged survival. The efficacy, potential candidates, and optimal dose-fractionation regimens of radiotherapy in this clinical scenario will be discussed. Additionally, radiotherapy can play a curative role as a concurrent therapy, consolidation therapy, and salvage therapy for patients with oligo-metastatic, oligo-residual, and oligo-progressive disease, respectively. Accumulating evidence from recent clinical trials, basic research, and translational investigations regarding the potentially curative roles of radiotherapy in NSCLC patients with oligo-metastatic disease will be summarized. Moreover, with the advent of various small molecular tyrosine kinase inhibitors (TKIs), the treatment efficacy and overall survival of oncogene-addicted NSCLC with brain metastases have been significantly improved, and the clinical value and optimal timing of cranial radiotherapy have become topics of much debate. Finally, synergistic antitumor interactions between radiotherapy and immunotherapy have been repeatedly demonstrated. Thus, the immune sensitizing role of radiotherapy in advanced NSCLC is also highlighted in this review.

Indexed as

Non-small cell lung cancer (NSCLC)palliative cancerperformance status (PS)radiotherapy

Identifiers

PMID33489808
PMCPMC7815368
OpenAlexW3112921784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.